계명대학교 의학도서관 Repository

Clinical Benefit of Low Molecular Weight Heparin for ST-segment Elevation Myocardial Infarction Patients Undergoing Primary Percutaneous Coronary Intervention with Glycoprotein IIb/IIIa Inhibitor

Metadata Downloads
Author(s)
Jung Sun ChoSung-Ho HerJu Yeal BaekMahn-Won ParkHyoung Doo KimMyung Ho JeongYoung keun AhnShung Chull ChaeSeung Ho HurTaek Jong HongYoung Jo KimIn Whan SeongJei Keon ChaeJay Young RhewIn Ho ChaeMyeong Chan ChoJang Ho BaeSeung Woon RhaChong Jim KimDonghoon ChoiYang Soo JangJunghan YoonWook Sung ChungJeong Gwan ChoKi Bae SeungSeung Jung Parkother Korea Acute Myocardial Infarction Registry Investigators
Keimyung Author(s)
Hur, Seung Ho
Department
Dept. of Internal Medicine (내과학)
Journal Title
Journal of Korean Medical Science
Issued Date
2010
Volume
25
Issue
11
Keyword
Myocardial InfarctionHeparinBlood PlateletsPrognosis
Abstract
The efficacy of low molecular weight heparin (LMWH) with low dose unfractionated
heparin (UFH) during percutaneous coronary intervention (PCI) with or without
glycoprotein (Gp) IIb/IIIa inhibitor compared to UFH with or without Gp IIb/IIIa inhibitor
has not been elucidated. Between October 2005 and July 2007, 2,535 patients with ST
elevation acute myocardial infarction (STEMI) undergoing PCI in the Korean Acute
Myocardial Infarction Registry (KAMIR) were assigned to either of two groups: a group
with Gp IIb/IIIa inhibitor (n=476) or a group without Gp IIb/IIIa inhibitor (n=2,059).
These groups were further subdivided according to the use of LMWH with low dose
UFH (n=219) or UFH alone (n=257). The primary end points were cardiac death or
myocardial infarction during the 30 days after the registration. The primary end point
occurred in 4.1% (9/219) of patients managed with LMWH during PCI and Gp IIb/IIIa
inhibitor and 10.8% (28/257) of patients managed with UFH and Gp IIb/IIIa inhibitor
(odds ratio [OR], 0.290; 95% confidence interval [CI], 0.132-0.634; P=0.006).
Thrombolysis In Myocardial Infarction (TIMI) with major bleeding was observed in
LMHW and UFH with Gp IIb/IIIa inhibitor (1/219 [0.5%] vs 1/257 [0.4%], P=1.00). For
patients with STEMI managed with a primary PCI and Gp IIb/IIIa inhibitor, LMWH is
more beneficial than UFH.
Keimyung Author(s)(Kor)
허승호
Publisher
School of Medicine
Citation
Jung Sun Cho et al. (2010). Clinical Benefit of Low Molecular Weight Heparin for ST-segment Elevation Myocardial Infarction Patients Undergoing Primary Percutaneous Coronary Intervention with Glycoprotein IIb/IIIa Inhibitor. Journal of Korean Medical Science, 25(11), 1601–1608. doi: 10.3346/jkms.2010.25.11.1601
Type
Article
ISSN
1011-8934
DOI
10.3346/jkms.2010.25.11.1601
URI
https://kumel.medlib.dsmc.or.kr/handle/2015.oak/34094
Appears in Collections:
1. School of Medicine (의과대학) > Dept. of Internal Medicine (내과학)
공개 및 라이선스
  • 공개 구분공개
파일 목록

Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.